ArticlePediatric research2026
Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6-23 months: phase III study (US/Puerto Rico).
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03691610 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA quadrivalent meningococcal tetanus toxoid-conjugate vaccine, MenACYW-TT, was developed to provide broad protection against invasive meningococcal disease across all age groups. We evaluated the immunogenicity and safety of MenACYW-TT as a two-dose series (1 + 1 schedule) co-administered with routine pediatric vaccines to infants from 6 months of age.
methodsThis phase III modified double-blind, randomized study (NCT03691610) enrolled healthy infants (n = 750) and toddlers (n = 200). Infants were randomized 1:1 to receive MenACYW-TT (Group 1) or another quadrivalent conjugate vaccine, MenACWY-CRM (Group 2) at ages 6-7 and 12-13 months, co-administered with routine vaccines. Toddlers were randomized 1:1 to receive MenACYW-TT (Group 3) or another quadrivalent conjugate vaccine, MenACWY-DT (Group 4) at ages 17-19 and 20-23 months. Functional antibodies against the four meningococcal serogroups were assessed by serum bactericidal antibody assay using human complement (hSBA). Safety was assessed up to 6 months post-vaccination.
resultsSeroresponse to MenACYW-TT was non-inferior to that with MenACWY-CRM against all four serogroups (seroresponse rates 30 days post-dose 2 were 89.4-99.3% and 82.9-97.7%, respectively). All vaccines were well tolerated.
conclusionsThese findings support MenACYW-TT administration as a two-dose series in children from 6 months of age. STUDY REGISTRATION: Clinicaltrials.gov: NCT03691610. IMPACT: When administered as a two-dose series (1 + 1 schedule), MenACYW-TT demonstrated comparable/higher immunogenicity to MenACWY-CRM (ages 6-7 and 12-13 months) and the safety profiles of these quadrivalent meningococcal vaccines were similar. MenACYW-TT was non-inferior to MenACWY-CRM in terms of seroresponse rates and proportion of participants with antibody titer ≥1:8 after a second dose at age 12-13 months. This phase III study is the first to confirm the safety and immunogenicity of MenACYW-TT in infants and supports its use as a two-dose series from 6 months of age.
Identifiers
41792337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.